Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.
A number of other research firms have also recently commented on TNXP. Raymond James Financial reiterated a “strong-buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, October 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Monday, October 26th. Finally, Canaccord Genuity Group began coverage on Tonix Pharmaceuticals in a research report on Monday, October 26th. They issued a “buy” rating and a $18.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $22.33.
View Our Latest Stock Analysis on Tonix Pharmaceuticals
Tonix Pharmaceuticals Price Performance
Shares of NASDAQ TNXP opened at $3.01 on Friday. Tonix Pharmaceuticals has a 1 year low of $2.90 and a 1 year high of $20.56. The company’s 50-day moving average is $7.72 and its 200 day moving average is $11.85. The stock has a market capitalization of $58.48 million, a P/E ratio of -0.25 and a beta of 1.90.
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($2.89) EPS for the quarter, missing the consensus estimate of ($2.39) by ($0.50). The company had revenue of $17.23 million during the quarter, compared to analysts’ expectations of $16.32 million. Tonix Pharmaceuticals had a negative return on equity of 80.97% and a negative net margin of 420.45%. Research analysts anticipate that Tonix Pharmaceuticals will post -10.42 earnings per share for the current year.
Insider Buying and Selling at Tonix Pharmaceuticals
In other news, CEO Seth Lederman purchased 2,000 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were purchased at an average cost of $13.79 per share, for a total transaction of $27,580.00. Following the purchase, the chief executive officer directly owned 11,005 shares in the company, valued at approximately $151,758.95. This represents a 22.21% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders acquired 8,000 shares of company stock worth $60,430. 2.00% of the stock is owned by corporate insiders.
Institutional Trading of Tonix Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE raised its stake in Tonix Pharmaceuticals by 101.1% during the 1st quarter. Bank of America Corp DE now owns 60,958 shares of the company’s stock valued at $838,000 after purchasing an additional 30,644 shares during the period. Bank of New York Mellon Corp purchased a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $533,000. Great Lakes Advisors LLC purchased a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $303,000. Empowered Funds LLC bought a new position in Tonix Pharmaceuticals in the 3rd quarter worth approximately $192,000. Finally, Integrated Wealth Concepts LLC bought a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $92,000. 82.26% of the stock is currently owned by institutional investors.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases. Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox.
Further Reading
- Five stocks we like better than Tonix Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
